Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Journal of clinical oncology, 2013-10, Vol.31 (28), p.3517-3524 [Peer Reviewed Journal]2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.48.4410 ;PMID: 23980084
Full text available